Formulation comprising emamectin

Abstract

The present invention relates to a composition comprising: (a) isocycloseram, (b) emamectin, and (c) a sulfonated lignin compound having a molecular weight up to 10,000 g / mol.

Description

FORMULATIONThis invention relates to a composition comprising emamectin, and preferably a composition comprising isocycloseram and emamectin. More particularly, this invention relates to formulations such as suspension concentrates (SC), flowable suspensions (FS), suspoemulsions (SE), suspension concentrate-capsule suspension blends (ZC), ready-to-use baits (RB), wettable powder (WP), water dispersible granules (WG), and water dispersible tablets (WT); to dilutions or dispersions of such formulations more particularly in a farmer’s spray -tank; and to use of such a composition to combating and / or control a pest.It has been found that mixing isocycloseram and emamectin present a number of problems with conventional approaches, such as for example formulating these two active ingredients is difficult especially in the presence of a photo-protecting agent, leading to stability issue.The aim of the present invention is to overcome the problems of the prior art techniques by proposing a composition comprising isocycloseram and emamectin, improving the long-term stability of said composition.To this end, an object of the present invention is to provide a composition comprising:(a) isocycloseram,(b) emamectin, preferably emamectin benzoate,(c) from 1 to 12% by weight of a sulfonated lignin compound (LI) having a molecular weight up to 10000 g / mol, over the total weight of the composition, and(d) from 0 to 12% by weight of a sulfonated lignin compound (L2) having a molecular weight up to 10,000 g / mol, over the total weight of the composition, the compound L2 being preferably different from the compound LI.Another object of the present invention is to provide a composition comprising:(a) isocycloseram,(b) emamectin, preferably emamectin benzoate,(c) a sulfonated lignin compound (LI) having a molecular weight up to 10,000 g / mol, and preferably from 1 to 12% by weight of the compound LI, over the total weight of the composition, and(d) a sulfonated lignin compound (L2) having a molecular weight up to 10,000 g / mol, the compound L2 being preferably different from the compound LI.Thanks to the combinations as defined above, such as the combination of isocy closeram, emamectin, and the compound LI, or the combination of isocy closeram, emamectin, and the compound L2, or the combination of isocy closeram, emamectin, the compound LI and the compound L2, all the above problems have been overcome. More particularly, the present invention is related to a composition comprising isocycloseram and emamectin, improving the long-term stability of said composition. Furthermore, a low degradation by UV light exposure can be guaranteed by said composition.Throughout this document, the expression “composition” stands for the various mixtures or combinations of active ingredients (a) and (b), for example in a single “ready-mix” form, in a combined spray mixture composed from separate formulations of the single active ingredient components, such as a “tank-mix”, and in a combined use of the single active ingredients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days. The order of applying the active ingredients (a) and (b) is not essential for working the present invention.Isocycloseram is an insecticidal agrochemical with the following CAS number: 2061933-85-3, and has the following chemical formula:Isocycloseram can comprise the isomer (5S,4R) which is 4-[(5S)-5-(3,5-dichloro-4-fluoro- phenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-N-[(4R)-2-ethyl-3-oxo-isoxazolidin-4-yl]-2- methyl-benzamide, and optionally at least one of the isomers selected among isomer (5S,4S), isomer (5R,4R), isomer (5R,4S), and any combinations thereof. In the present invention, theisomer (5S,4S) is 4-[(5S)-5-(3,5-dichloro-4-fluoro-phenyl)-5-(trifluoromethyl)-4H-isoxazol-3- yl]-N-[(4S)-2-ethyl-3-oxo-isoxazolidin-4-yl]-2-methyl-benzamide; the isomer (5R,4R) is 4- [(5R)-5-(3,5-dichloro-4-fluoro-phenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-N-[(4R)-2- ethyl-3-oxo-isoxazolidin-4-yl]-2-methyl-benzamide; and the isomer (5R,4S) is 4-[(5R)-5-(3,5- di chi oro-4-fluoro-phenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-N-[(4S)-2-ethyl -3-oxo- isoxazolidin-4-yl]-2-methyl-benzamide. When isocycloseram further comprises at least one of the isomers selected among isomer (5S,4S), isomer (5R,4R), isomer (5R,4S), and any combinations thereof, isocycloseram can comprise a molar proportion of the isomer (5S,4R) greater than 50%, e.g. at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%, over the total amount of the isomers (5S,4R), (5S,4S), (5R,4R) and (5R,4S).The molar proportion of the isomer (5S,4S) can be less than 50%, e.g. at most 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5% or 0.1%, over the total amount of the isomers (5S,4R), (5S,4S), (5R,4R) and (5R,4S).The molar proportion of the isomer (5R,4R) can be less than 50%, e.g. at most 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5% or 0.1%, over the total amount of the isomers (5S,4R), (5S,4S), (5R,4R) and (5R,4S).The molar proportion of the isomer (5R,4S) can be less than 50%, e.g. at most 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5% or 0.1%, over the total amount of the isomers (5S,4R), (5S,4S), (5R,4R) and (5R,4S).The composition according to the present invention can comprise from 1% to 30% by weight of isocycloseram, preferably from 10% to 20% by weight of isocycloseram, and more preferably from 15% to 20% by weight of isocycloseram, over the total weight of the composition.The active ingredient (b) is emamectin, preferably an emamectin salt, and more preferably a benzoate salt of emamectin, well known under the name emamectin benzoate with the following CAS number: 155569-91-8.The composition according to the present invention can comprise from 0.1% to 20% by weight of emamectin, preferably from 1% to 10% by weight of emamectin, and more preferably from 2% to 8% by weight of emamectin, over the total weight of the composition.In a particular embodiment according to the present invention, the composition can comprise a weight ratio of isocycloseram to emamectin from 1 :1 to 10:1, preferably from 1 :1 to 8: 1, preferably from 1 : 1 to 5: 1, and more preferably 2:1, 3: 1 or 4: 1.In the present invention, the sulfonated lignin compound is more particularly a water-soluble anionic polymer which can be formed as by-product in the sulphite pulping process.The sulfonated lignin compound may comprise different metal or ammonium ions as counter cations of the sulfonate groups, such as for example copper, zinc, calcium, sodium, potassium, magnesium, or aluminum. The most preferred counter cation is sodium.The sulfonated lignin compound can be defined as including lignosulfonate, lignosulfonic acid, lignosulfuric acid, lignin sulfonate, ligninsulfonic acid, or other expressions well-known in the art. More preferably, the sulfonated lignin compound can be a salt of lignosulfonic acid, such as sodium lignosulfonate or calcium lignosulfonate, the most preferred one being sodium lignosulfonate.The sulfonated lignin compound according to the present invention has a molecular weight up to 10,000 g / mol, and preferably a molecular weight of at least 1,000 g / mol.In the present invention, the expression “a molecular weight” means an average molecular weight (i.e. a molecular weight approximately of). Molecular weight of a polymer, or in other words the molar mass, can be easily determined by method well-known in the art, such as gel permeation chromatography (GPC).In a preferred embodiment, the sulfonated lignin compound LI can have a molecular weight from 1,000 to 8,000 g / mol, preferably from 2,000 to 7,000 g / mol, preferably from 2,500 to4.500 g / mol, and more preferably from 3,000 to 4,000 g / mol.In a preferred embodiment, the sulfonated lignin compound L2 can have a molecular weight from 1,000 to 8,000 g / mol, preferably from 2,000 to 7,000 g / mol, preferably from 4,500 to6.500 g / mol, and more preferably from 5,000 to 6,000 g / mol.The sulfonated lignin compound according to the present invention can have a particular degree of sulfonation.In the present invention, the sulfonation degree can be determined according to the method described in Myrvold, B. (2013), Salting-out and salting-in experiments with lignosulfonates (LSs), Holzforschung, 67(5), 549-557.More particularly, the total sulfur and inorganic sulfur present in a sulfonated lignin compound (i.e. a lignosulfonate) are measured. The organic sulfur is the difference between the total sulfur and inorganic sulfur. The organic sulfur is typically reported as percentage by weight based on dry matter of lignosulfonate. This is converted to mol / kg of lignosulfonate, which corresponds to the sulfonation degree - as defined in the below equation:In a preferred embodiment, the sulfonated lignin compound LI can have a sulfonation degree from 0.1 to 5.0 mol / kg of the compound LI, and preferably from 0.2 to 3.0 mol / kg of the compound LI, preferably from 0.1 to 1.5 mol / kg of the compound LI, and more preferably from 0.2 to 1.0 mol / kg of the compound LI.In a preferred embodiment, the sulfonated lignin compound L2 can have a sulfonation degree from 0.1 to 5.0 mol / kg of the compound L2, and preferably from 0.2 to 3.0 mol / kg of the compound L2, preferably from 1.6 to 3.0 mol / kg of the compound L2, and more preferably from 2.0 to 3.0 mol / kg of the compound L2.The composition according to the present invention can comprise from 2 to 10% by weight of the compound LI, and preferably from 4 to 9% by weight of the compound LI, over the total weight of the composition, and / or can comprise from 2 to 10% by weight of the compound L2, and preferably from 4 to 9% by weight of the compound L2, over the total weight of the composition.In a particular embodiment, the composition can comprise:(a) from 1% to 30% by weight of isocycloseram, and preferably from 10% to 20% by weight of isocycloseram, over the total weight of the composition,(b) from 0.1% to 20% by weight of emamectin, and preferably from 1% to 10% by weight of emamectin, over the total weight of the composition, and(c) from 1 to 12% by weight of the compound LI, preferably from 2 to 10% by weight of the compound LI, and more preferably from 4 to 9% by weight of the compound LI, over the total weight of the composition.In a more preferred embodiment, said composition can comprise only one sulfonated lignin compound.In another particular embodiment, the composition can comprise:(a) from 1% to 30% by weight of isocycloseram, and preferably from 10% to 20% by weight of isocycloseram, over the total weight of the composition,(b) from 0.1% to 20% by weight of emamectin, and preferably from 1% to 10% by weight of emamectin, over the total weight of the composition, and(c) from 1 to 12% by weight of the compound L2, preferably from 2 to 10% by weight of the compound L2, and more preferably from 4 to 9% by weight of the compound L2, over the total weight of the composition.In a more preferred embodiment, said composition can comprise only one sulfonated lignin compound.In another particular embodiment, the composition can comprise:(a) from 1% to 30% by weight of isocycloseram, and preferably from 10% to 20% by weight of isocycloseram, over the total weight of the composition,(b) from 0.1% to 20% by weight of emamectin, and preferably from 1% to 10% by weight of emamectin, over the total weight of the composition,(c) from 1 to 12% by weight of the compound LI, preferably from 2 to 10% by weight of the compound LI, and more preferably from 4 to 9% by weight of the compound LI, over the total weight of the composition, and(d) from 1 to 12% by weight of the compound L2 preferably, from 2 to 10% by weight of the compound L2, and more preferably from 4 to 9% by weight of the compound L2, over the total weight of the composition.The composition according to the present invention can further comprise at least one of the components, preferably at least two of the components, and more preferably the three components, selected among a polyoxyalkylene copolymer, an acrylic graft copolymer, and an oxygenated hydrocarbon.In the present invention, the polyoxyalkylene copolymer can be obtained from at least two different alkylene oxides, such as from ethylene oxide and propylene oxide monomers.The polyoxyalkylene copolymer can be more preferably a polyoxyalkylene block copolymer of the AB, ABA, BAB, or ABABA type.More particularly, the polyoxyalkylene copolymer can be prepared by ring-opening polymerization of the corresponding cyclic ethylene oxide and propylene oxide monomers. Typically, the ring-opening polymerization is initiated by addition of water and alkali hydroxides, such as sodium hydroxide and potassium hydroxide. The block structure of the copolymer is formed by first polymerizing a polymer block using one monomer, before adding a second monomer to form further polymer blocks.In a preferred embodiment, the polyoxyalkylene copolymer can be an ethylene oxi de-propylene oxi de-ethylene oxide block copolymer (EO-PO-EO block copolymer), or in other words apoly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer or a poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol) block copolymer.The polyoxyalkylene copolymer of the invention, and more particularly the EO-PO-EO block copolymer, can have a molecular weight from 1,000 to 15,000 g / mol, and more preferably from 3,000 to 7,000 g / mol.In a first embodiment, the EO-PO-EO block copolymer can have a polypropylene oxide molecular weight from 900 to 4,000 g / mol, and preferably from 2,000 to 4,000 g / mol. In other words, the polypropylene oxide molecular weight is the molecular weight of the polypropylene oxide) block of the EO-PO-EO block copolymer.In a second embodiment, the EO-PO-EO block copolymer can have an ethylene oxide content from 10 to 80%, and preferably from 30 to 50%, over the total weight of the copolymer. In other words, the ethylene oxide content is the percentage of the poly(ethylene oxide) block in the EO-PO-EO block copolymer.In a third embodiment, the EO-PO-EO block copolymer can have the features of the first embodiment and the features of the second embodiment.Examples include the GENAPOL® PF series (CLAMANT), the PLURONIC® series (BASF), the SYNPERONIC® PE series (CRODA), or the TOXIMUL® series (STEPAN).The composition of the present invention can comprise from 0.1% to 5.0% by weight of the polyoxyalkylene copolymer, preferably from 0.5% to 2.0% by weight of the polyoxyalkylene copolymer, and more preferably around 1% by weight of the poly oxy alkylene copolymer, over the total weight of the composition.The acrylic graft copolymer has typically a comb- or star-like structure, and preferably a comblike structure.Graft copolymers are branched copolymers wherein the components forming the side chains are structurally different from the components forming the main chain.Comb-like polymers comprise of a main chain (backbone) which contains branch points from each of which a linear side chain emanates.Star-like polymers comprise of a multifunctional centre from which at least three polymer chains radiate.In a preferred embodiment, the acrylic graft copolymer can be an amphipathic copolymer.More particularly, the acrylic graft copolymer comprises at least one component A, which is solvated by an aqueous medium (hydrophilic part), and at least one other component B which is hydrophobic.Suitable acrylic graft copolymers may comprise polyethylene glycol, mono-methyl ethers of polyethylene glycol, poly(vinyl pyrrolidone), poly(acrylamide) or poly(vinyl alcohol) as hydrophilic side chain, while the hydrophobic backbone may comprise polymers and copolymers of styrene, methyl acrylate, methyl methacrylate, ethyl acrylate, 2-ethylhexyl acrylate, lauryl methacrylate, or vinyl acetate.Such acrylic graft copolymers can for example be prepared by converting the mono-methyl ether of a polyethylene glycol to the acrylic or methacrylic ester, which is then subjected to radical polymerization with other unsaturated monomers such as styrene, ethyl acrylate, or methyl methacrylate. It is also possible to prepare such acrylic graft copolymers by reacting a hydrophobic polymer backbone, which consists chemically reactive sites such as carboxyl, hydroxy, or amine groups, with monomeric alkylene oxides, such as ethylene oxide and propylene oxide, to form hydrophilic side chains.More preferably, the acrylic graft copolymer is a non-ionic polymer, and more particularly with a comb-like structure.In the present invention, the acrylic graft copolymer can comprise polyethylene glycol and / or mono-ether polyethylene glycol side chains.The acrylic graft copolymer can also comprise a backbone obtained from acrylate and / or methacrylate monomers.Even more preferably, the acrylic graft copolymer can comprise a backbone obtained from acrylate and / or methacrylate monomers, and side chains comprising polyethylene glycol and / or mono-ether polyethylene glycol, giving more particularly the polymer a comb-like structure.For example, the acrylic graft copolymer of the present invention can be Atlox 4913™ supplied by CRODA, or Tersperse 2500™ supplied by HUNTSMAN.The composition of the present invention can comprise from 0.01% to 10.0% by weight of the acrylic graft polymer, preferably from 0.01 to 5.0% by weight of the acrylic graft polymer, preferably from 0.1% to 2.0% by weight of the acrylic graft polymer, preferably from 0.1% to 1.0% by weight of the acrylic graft polymer, and more preferably around 0.4 % by weight of the acrylic graft polymer, over the total weight of the composition.The oxygenated hydrocarbon compound can be selected among alkyl ether compounds, alkyl ester compounds, and any mixture thereof; and preferably among polyethylene glycol alkyl ether, sulfonated alkyl ester compounds, and any mixture thereof. In other words, the oxygenated hydrocarbon compound is preferably different from the polyoxyalkylene copolymer and from the acrylic graft copolymer.The polyethylene glycol alkyl ether can be obtained by reacting alcohols with ethylene oxide. Suitable alcohols are linear or branched aliphatic alcohols with a chain length from C2 to Cl 5, preferably with a chain length from C7 to Cl 1, and more preferably with a chain length of C9 or CIO. An example can be Rhodasurf DA / 630-E™ supplied by SOLVAY-RHODIA,The sulfonated alkyl ester compound can be a sulfosuccinate ester or a salt of a sulfosuccinate ester. An example can be Aerosol™ OT-B, supplied by SOLVAY-RHODIA.The composition of the present invention can comprise from 0.01% to 5.0% by weight of the oxygenated hydrocarbon compound, preferably from 0.05% to 2.0% by weight of the oxygenated hydrocarbon compound, preferably from 0.1% to 1.0% by weight of the oxygenated hydrocarbon compound, and more preferably around 0.4% by weight of the oxygenated hydrocarbon compound, over the total weight of the composition.In the present invention, the composition may further comprise water.In a particular embodiment, the composition according to the present invention can further comprise, over the total weight of the composition:(e) from 0.01% to 10.0% by weight of polyoxyalkylene copolymer, preferably from 0.1% to 5.0% by weight of polyoxyalkylene copolymer, and more preferably from 0.5% to 2.0% by weight of polyoxyalkylene copolymer,(f) from 0.01% to 10.0% by weight of the acrylic graft polymer, preferably from 0.01 to 5.0% by weight of the acrylic graft polymer, preferably from 0.1% to 2.0% by weight of the acrylic graft polymer, and more preferably from 0.1% to 1.0% by weight of the acrylic graft polymer, and(g) from 0.01% to 5.0% by weight of the oxygenated hydrocarbon compound, preferably from 0.05% to 2.0% by weight of the oxygenated hydrocarbon compound, and more preferably from 0.1% to 1.0% by weight of the oxygenated hydrocarbon compound, and(h) optionally water.In a first preferred embodiment, the composition can comprise, over the total weight of the composition:(a) from 1% to 30% by weight of isocycloseram, and preferably from 10% to 20% by weight of isocycloseram,(b) from 0.1% to 20% by weight of emamectin, and preferably from 1% to 10% by weight of emamectin,(c) from 1 to 12% by weight of the compound LI, preferably from 2 to 10% by weight of the compound LI, and more preferably from 4 to 9% by weight of the compound LI,(e) from 0.01% to 10.0% by weight of polyoxyalkylene copolymer, preferably from 0.1% to 5.0% by weight of polyoxyalkylene copolymer, and more preferably from 0.5% to 2.0% by weight of polyoxyalkylene copolymer,(f) from 0.01% to 10.0% by weight of the acrylic graft polymer, preferably from 0.01 to 5.0% by weight of the acrylic graft polymer, preferably from 0.1% to 2.0% by weight of the acrylic graft polymer, and more preferably from 0.1% to 1.0% by weight of the acrylic graft polymer, and(g) from 0.01% to 5.0% by weight of the oxygenated hydrocarbon compound, preferably from 0.05% to 2.0% by weight of the oxygenated hydrocarbon compound, and more preferably from 0.1% to 1.0% by weight of the oxygenated hydrocarbon compound, and(h) optionally water.In a second preferred embodiment, the composition can comprise, over the total weight of the composition:(a) from 1% to 30% by weight of isocycloseram, and preferably from 10% to 20% by weight of isocycloseram,(b) from 0.1% to 20% by weight of emamectin, and preferably from 1% to 10% by weight of emamectin,(c) from 1 to 12% by weight of the compound LI, preferably from 2 to 10% by weight of the compound LI, and more preferably from 4 to 9% by weight of the compound LI,(d) from 1 to 12% by weight of the compound L2 preferably, from 2 to 10% by weight of the compound L2, and more preferably from 4 to 9% by weight of the compound L2.(e) from 0.01% to 10.0% by weight of polyoxyalkylene copolymer, preferably from 0.1% to 5.0% by weight of polyoxyalkylene copolymer, and more preferably from 0.5% to 2.0% by weight of polyoxyalkylene copolymer,(f) from 0.01% to 10.0% by weight of the acrylic graft polymer, preferably from 0.01 to 5.0% by weight of the acrylic graft polymer, preferably from 0.1% to 2.0% by weight of the acrylic graft polymer, and more preferably from 0.1% to 1.0% by weight of the acrylic graft polymer, and(g) from 0.01% to 5.0% by weight of the oxygenated hydrocarbon compound, preferably from 0.05% to 2.0% by weight of the oxygenated hydrocarbon compound, and more preferably from 0.1% to 1.0% by weight of the oxygenated hydrocarbon compound, and(h) optionally water.The composition of the present invention may further comprise one or more formulation additives well-known in the art, usually employed for this purpose in agrochemical compositions.In particular, the formulation additives can be selected among an anti-freeze agent, an anti -foam agent, an anti-bacterial agent (or biocide), a viscosity modifier (or thickener), a pH modifier, and any mixture thereof.More preferably, the composition can comprise the following formulation additives: an antifreeze agent, an anti-foam agent, an anti-bacterial agent (or biocide), and a viscosity modifier (or thickener).The composition according to the present invention can comprise from 0.1 to 20% by weight of formulation additive(s) over the total weight of the composition.Suitable anti-freeze agents can be for example selected from urea, glycerol, propylene glycol, and any mixture thereof. Anti-freeze agent(s) can be added in total from 0.05 to 5% by weight, and preferably 0.1 to 2% by weight, over the total weight of the composition.Suitable anti-foam agents can be for example selected from silicone oils (such as for example polydimethylsiloxane), magnesium stearate, and any mixture thereof. Anti-foam agent(s) can be added in total from 0.05 to 5% by weight, and preferably 0.1 to 2% by weight, over the total weight of the composition.Suitable preservatives can be for example selected from l,2-benzisothiazol-3-one, 5-chloro-2- methyl-4-isothiazolin-3-one, 2-methyl-4-isothiazolin-3-one, 2-bromo-2-nitropropan-l,3-diol, and any mixture thereof. Preservative(s) can be added in total from 0.05 to 5% by weight, and preferably 0.1 to 2% by weight, over the total weight of the composition.Suitable viscosity modifiers (or thickeners) can be for example selected from silicates, phyllosilicates (such as for example montmorillonite-type clay), polysaccharides (such as for example xanthan gum), cellulose (such as for example cellulose fibrils), and any mixture thereof. Cellulose fibrils can be more particularly microfibrillated cellulose, fibrillated cellulose suspended in water, or microfibrillated cellulose suspended in water, such as for example the cellulose fibrisl commercialized by Borregaard under the name Exilva. Preferably, xanthan gum and / or cellulose fibrils can be used as thickener(s). Thickener(s) can be added in total from 0.05 to 5% by weight, preferably 0.1 to 2% by weight, and more preferably 0.5 to 1.5% by weight, over the total weight of the composition.Other suitable formulation additives include amongst others known to the person skilled in the art, antioxidant, emulsifying agent, colourant (or pigment), perfume, adjuvant, attractant,binder, buffer, solid support (carrier), coating agent, deodorant, emetic agent, inorganic filler, safener, organic solvent, photo-protecting agent, and any mixture thereof.The composition of the present invention may further comprise an additional agrochemical, or in other words a third agrochemical. The additional agrochemical can be an insecticide, a fungicide, an herbicide, a synergist, a plant growth regulator, a nematicide, a plant nutrient, a plant fertilizer, a biological, and a mixture thereof.In a particular embodiment, the composition of the present invention can further comprise an additional insecticide selected from abamectin, bifenthrin, broflanilide, chlorantraniliprole, chlorfenapyr, cyantraniliprole, cypermethrin, deltametrin, ethiprole, fluxametamide, gamma- cyhalothrin, lambda-cyhalothrin, lufenuron, methoxyfenozide, pymetrozine, spinetoram, spinosad, sulfoxaflor, tefluthrin, thiamethoxam, and any mixtures thereof.In another paticular embodiment, the composition of the present invention can further comprise a biological selected from Bacillus species. Bacillus species are insecticidally and / or nematicidally active bacteria, and can include for example Bacillus firmus. Bacillus cercus. Bacillus sublilis. or Bacillus thuringiensis. The most preferred Bacillus species is Bacillus thuringiensis. and more particularly Bacillus thuringiensis var. kurstaki or Bacillus thuringiensis var. tenebrionis.More preferably the composition can further comprise an additional insecticide selected among bifenthrin, chlorantraniliprole, chlorfenapyr, cyantraniliprole, cypermethrin, ethiprole, lambda- cyhalothrin, lufenuron, spinosad, tefluthrin, and any mixtures thereof.The weight ratio of isocycloseram to the additional insecticide can be from 1 : 100 to 100: 1, preferably from 1 :20 to 20: 1, preferably from 1 :10 to 10: 1, preferably from 1 : 1 to 1 : 10, preferably from 1 :1 to 1 :6, and more preferably 1 :2, 1 :3, 1 :4 or 1 :5.The weight ratio of isocycloseram to the biological can be from 1 :2000 to 1 :2, preferably from 1 : 1000 to 1 : 100, preferably from 1 :400 to 1 : 10, and more preferably from 1 :200 to 1 : 100.The composition of the present invention may comprise a suitable amount of one or several of the above-mentioned ingredient(s) to obtain the respective properties, when appropriate.In another object of the present invention, the composition can be advantageously used to prepare a suspension concentrate (SC), a flowable suspension (FS), a suspoemulsion (SE), suspension concentrate-capsule suspension blends (ZC), a ready-to-use bait (RB), wettable powder (WP), water dispersible granules (WG) (extruded granules and pepites), or water dispersible tablets (WT). The most preferred formulation type is a suspension concentrate.In a particular embodiment, the composition of the present invention may relate to:- a concentrate designed to be added to a farmer’s spray tank of water or it may be applied directly without further dilution, or- a suspension produced in a farmer’s spray tank of water when a concentrate is mixed with water in the spray tank.Another object of the present invention is the use of the composition according to the present invention for combating and / or controlling (i.e. containing or destroying) a pest which occur in particular on plants, especially on perennial and annual crops of useful plants susceptible to attack by such pests including food crops and herbaceous and woody ornamentals in agriculture, in horticulture and in forests, or on organs, such as fruits, flowers, foliage, stalks, tubers or roots, of such plants, and in some cases even plant organs which are formed at a later point in time remain protected against these pests.More preferably, the present invention relates to a method of combating and / or controlling a pest, which comprises applying to the pest, to a locus of the pest, or to a plant susceptible to attack by the pest, the composition according to any one of the preceding claims.Said method can be applied in spraying the composition, for example dispensed from a spray container for foliar application.Said method can involve an effective amount of the composition applied at a rate of:- from 1 g to 100 g of isocy closeram per hectare, preferably from 10 g to 50 g of isocy closeram per hectare, preferably from 10 g to 20 g of isocy closeram per hectare, and more preferably around 17 g of isocy closeram per hectare; and- from 1 g to 50 g of emamectin per hectare, preferably from 1 g to 20 g of emamectin per hectare, preferably from 1 g to 10 g of emamectin per hectare, and more preferably around 4 g of emamectin per hectare.More particularly, the weight rate of isocycloseram is inferior to the the weight rate of emamectin, preferably the weight rate of isocycloseram is at least 2 times lower than the weight rate of emamectin, preferably the weight rate of isocycloseram is at least 3 times lower than the weight rate of emamectin, and more preferably the weight rate of isocycloseram is around 4 times lower than the weight rate of emamectin.The composition according to the present invention can also be used for combating and / or controlling (i.e. containing or destroying) a pest which occur in particular in soil and / or on plant propagation material.More particularly, the composition according to the present invention can be used as a seed treatment formulation, or in other words a plant propagation material can be treated with the composition according to the invention. The term "plant propagation material" is understood to denote all the generative parts of the plant, such as seeds, which can be used for the multiplication of the latter including vegetative plant material such as cuttings. There may be mentioned, as plant propagation material, seeds (in the strict sense), roots, fruits, tubers, bulbs, rhizomes, parts of plants. The plant propagation material can be treated with the composition of the invention before the material is sown or planted. Alternatively, the plant propagation material may be treated with the composition of the invention during sowing or planting. Additionally, the composition of the invention may be applied to the previously treated propagation material before or during its planting. The composition of the invention may be applied during the sowing of the seed. The composition may also be used to plant propagation material derived from plants grown in a green house and / or during transplantation.Another object of the present invention is the use of the composition according to the present invention in the field of tree injection / trunk treatment for all ornamental trees as well all sort of fruit and nut trees.In the present invention, the above methods and uses preferably exclude treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body.The term "plant" as used in the present description includes seedlings, bushes and trees. Suitable target crops are, in particular, cereals, such as wheat, barley, rye, oats, rice, maize (e.g. field corn, popcorn, com), millet or sorghum; beet, such as sugar or fodder beet; fruit, for example pomaceous fruit, stone fruit or soft fruit, such as apples, pears, plums, peaches, almonds, cherries or berries, for example strawberries, raspberries or blackberries; leguminous crops, such as beans, dry beans, lentils, peas or soya (soya beans); oil crops, such as oilseed rape, mustard, poppies, olives, sunflowers, coconut, castor, cocoa or ground nuts; cucurbits, such as pumpkins, cucumbers, melons, watermelons or squashes; fibre plants, such as cotton, flax, hemp or jute; citrus fruit, such as oranges, lemons, grape (grapefruit, grapevine) or tangerines; vegetables, such as spinach, lettuce, asparagus, cabbages, broccolis, cauliflowers, carrots, onions, tomatoes, potatoes, eggplants, peppers or bell peppers; Lauraceae, such as avocado, Cinnamonium or camphor; and also tobacco, nuts, coffee, sugarcane, tea, hops, the plantain family and latex plant.In a preferred embodiment, the plant can be selected from:- cereals, such as wheat, barley, rye, oats, rice, maize (e.g. field com, popcorn, corn), millet or sorghum; and more preferably corn and wheat;- leguminous crops, such as beans, dry beans, lentils, peas or soya (soya beans); and more preferably soya (soya beans) or dry beans;- fibre plants, such as cotton, flax, hemp or jute; and more preferably cotton;- vegetables, such as spinach, lettuce, asparagus, cabbages, broccolis, cauliflowers, carrots, onions, tomatoes, potatoes, eggplants, peppers or bell peppers; and more preferably potatoes;- fruits, such as apple, pear, plum or grape; and- coffee and sugarcane.In a further preferred embodiment, transgenic plants and plant cultivars obtained by genetic engineering methods, if appropriate in combination with conventional methods (Genetically Modified Organisms), and parts thereof, can be treated by the pesticidal composition of the invention. Particularly preferably, plants of the plant cultivars which are in each case commercially available or in use are treated according to the invention. Plant cultivars are understood as meaning plants having novel properties ("traits") which have been obtained by conventional breeding, by mutagenesis or by recombinant DNA techniques. These can be cultivars, bio- or genotypes.The genetic modified crops can be described in the following website https: / / www.isaaa.org / gmapprovaldatabase, incorporated by reference therein.For example, when considering soybean, the genetic modified crops can be selected from:oun up ea y er y nC d MON 4 326In the present invention, the term “locus” as used herein means fields in or on which plants are growing, or where seeds of cultivated plants are sown, or where seed will be placed into the soil. It includes soil, seeds, and seedlings, as well as established vegetation.The term "pest" as used in the present description includes more preferably species from Lepidoptera order, Hemiptera order, Thysanoptera order, Coleoptera order, Diptera order, and mites. The Lepidoptera order can be from the Noctuidae family, and more preferably from theSpodoptera genus, such as for example Spodoptera frugiperda, and Spodoptera eridania, from the Helicoverpa genus such as for example Helicoverpa armigera, from the Chrysodeixis genus, such as for example Chrysodeixis includens, from the Diatraea genus, such as for example Diatraea saccharalis and from the Tula genus, such as for example Tula absoluta.The Coleoptera order can be selected from Chrysomelidae family (such as for example Diabrotica sp., Leptinotarsa sp., Phyllotreta sp., Chaetocnema sp.), Scarabidae family (such as for example Phyllophaga sp., Cyclocephala sp., Popilia sp.), Curculionidae family (such as for example Anthonomus sp., Sphenopherus sp., Otiorhynchus sp.), and Nitidulidae family (such as for example Meligethes sp.).The Diptera order can be selected from family Agromyzidae (such as for example Liriomyza huidobr easts'). The Hemiptera order (Heteroptera suborder) can be selected from Pentatomidae family such as for example Dichelops melacanthus, Euschistus heros; from Cicadellidae family such as for example Dalbulus maidis, Peregrinus maidis.The Thysanoptera order or thrips can be selected from Thripidae family such as for example Frankliniella schullzei. Caliothrips phaseoli.Mites can be from the Tetranychidae family such as for example Tetranychus urticae.Another object of the present invention is a process to prepare a composition according to the present invention, wherein the process comprises the following steps: i. mixing the formulation additive(s), optionally with water, the formulation additive(s) being more preferably selected from one or several anti-freeze agent(s), one or several biocide(s), one or several anti-foam agent(s), one or several thickener(s), and any mixture thereof, to obtain an homogenized mixture; ii. mixing the sulfonated lignin compound(s) (LI and / or L2) and the mixture obtained in step i, to solubilize the sulfonated lignin compound(s); iii. mixing: o isocycloseram and / or emamectin, as active ingredient(s), and o one or several components selected from a polyoxyalkylene copolymer, an acrylic graft copolymer, and an oxygenated hydrocarbon, and o optionally with water; iv. mixing the mixture obtained in step ii and the mixture(s) obtained in step iii, to obtain the composition according to the present invention.In step i, the mixture can be done with a paddle stirrer or a saw-toothed mixer, and the mixing temperature can be done at room temperature (i.e. 25°C).In step ii, the mixture can be done with a paddle stirrer, and the mixing temperature can be done at room temperature (i.e. 25°C). The addition of the sulfonated lignin compound(s) can be preferably done portionwise, over a certain period of time (30-60 minutes), in order to slowly incorporate the sulfonated lignin compound(s) into the mixture obtained in step i.The solubilization of the sulfonated lignin compound(s) can be easily identify by method well- known in the art, such as for exemple by a visible assessment in checking that there is no visible lumps in the mixture obtain in step ii.In step iii, the mixture including isocycloseram and / or emamectin can be done with a high shear mixing (Silverson high-shear mixer, 5000 rpm), and the mixing temperature can be done at room temperature (i.e. 25°C).The mixture can be sheared continuously until it was found to be able to pass through a 150 pm sieve. The mixture can then be transferred to a horizontal bead mill and milled until the following particle size D(v,50) was achieved. The mixture obtained in step iii can preferably have particle size D(v,50) of less than 3 pm, and more preferably have particle size D(v,50) less than 2 pm. The particle size can be measured by techniques well-know in the art, such as for example in using a Malvern Mastersizer 3000, laser diffraction particle size analyser.In step iii, the mixture composition can be prepared by mixing together a first composition comprising isocysloseram and a second composition comprising emamectin, wherein the first and second compositions are respectively prepared as detailed for the mixture in step iii above. In a first particular embodiment, isocycloseram, emamectin, and one or several components selected from a polyoxyalkylene copolymer, an acrylic graft copolymer, and an oxygenated hydrocarbon, and optionally water, are mixed together.In a second particular embodiment,A. isocycloseram and one or several components selected from a polyoxyalkylene copolymer, an acrylic graft copolymer, and an oxygenated hydrocarbon, and optionally water, are mixed together to obtain a mixture a, andB. emamectin and one or several components selected from a polyoxyalkylene copolymer, an acrylic graft copolymer, and an oxygenated hydrocarbon, and optionally water, are mixed together to obtain a mixture b.The mixing steps i and ii can be done in a first appropriate vessel, and the mixing step iii can be done in one or several second appropriate vessel(s) different from the first vessel.In step iv, the mixture can be done with a paddle stirrer, and the mixing temperature can be done at room temperature (i.e. 25°C).The mixing of step iv can be more particularly as follows: mixing the mixture obtained in step ii and the mixture obtained in step iii according to the first particular embodiment, or mixing the mixture obtained in step ii and the mixtures obtained in step iii according to the second particular embodiment (i.e. mixture a and mixture b).More preferably, in the mixing step iv, the mixture of step iii can be added into the mixture of step ii.The pH of the mixture obtained in step iv can be from from 7.5 to 9.5, preferably from 7.5 to 9, and even more preferably around 8.Another object of the present invention is to provide a composition, and preferably an aqueous composition, comprising:(b) emamectin, preferably emamectin benzoate, optionally in an amount of from 40 to 60% by weight over the total weight of the composition;(e) a poly oxyalkylene copolymer in an amount of from 1 to 4% by weight over the total weight of the composition;(f) an acrylic graft copolymer in an amount of from 1 to 4% by weight over the total weight of the composition;(g) an oxygenated hydrocarbon in an amount of from 0.5 to 1.5% by weight over the total weight of the composition; and(h) water.The components (b), (e), (f) and (g) are further defined in the present description above.In a further embodiment, the composition, and preferably the aqueous composition, consists essentially, preferably consists, of:(b) emamectin and, optionally, one or more other active ingredients, wherein the total amount of active ingredients is from 40 to 60 % by weight over the total weight of the composition;(e) a polyoxy alkylene copolymer in an amount of from 1 to 4 % by weight over the total weight of the composition;(f) an acrylic graft copolymer in an amount of from 1 to 4 % by weight over the total weight of the composition;(g) an oxygenated hydrocarbon in an amount of from 0.5 to 1.5 % by weight over the total weight of the composition; and(h) water.The components (b), (e), (f) and (g) are further defined in the present description above.In the embodiment wherein the composition comprises emamectin and one or more other active ingredients, the one or more active ingredients can be selected from another insecticide, examples of which are abamectin, bifenthrin, broflanilide, chlorantraniliprole, chlorfenapyr, cyantraniliprole, cypermethrin, deltametrin, ethiprole, fluxametamide, gamma-cyhalothrin, isocy closeram, lambda-cyhalothrin, lufenuron, methoxyfenozide, pymetrozine, spinetoram, spinosad, sulfoxaflor, tefluthrin, and thiamethoxam.In a particular embodiment wherein the composition comprises, and preferably consists of: (b) as active ingredient(s), emamectin and, optionally, one or more other active ingredients, wherein the total amount active ingredients is from 40 to 60 weight % based on the weight of the composition;(e) a polyoxyalkylene copolymer in an amount of from 1 to 4% by weight based on the weight of the composition;(f) an acrylic graft copolymer in an amount of from 1 to 4% by weight based on the weight of the composition;(g) an oxygenated hydrocarbon in an amount of from 0.5 to 1.5% by weight based on the weight of the composition; and(h) water; the only one active ingredient or each of the actve ingredients has a particle size D(v,50) of less than 2 pm, in using a Malvern Mastersizer 3000, laser diffraction particle size analyser.The components (b), (e), (f) and (g) are further defined in the present description above. The compositions comprising (b), (e), (f), (g) and (h) can be prepared according to the steps i to iv as described in the present invention above. Isocycloseram or other pesticidal active ingredient(s) can be added in step iii and / or after step iv.Examples:The following non-limiting examples demonstrate the improved behaviour associated with the compositions of the present invention.1. Compositions comprising isocycloseram and emamectinThe compositions Cl, Il and 12 gathered in table 1 are suspension concentrates, the compositions II and 12 being according to the present invention, while the composition Cl being a comparative composition.The components used in table 1 are detailed below:Isocycloseram (CAS number: 2061933-85-3),Emamectin benzoate (CAS number: 155569-91-8),Sulfonated lignin compound LI is the product Vanisperse CB (CAS number: 8061- 51-6), supplied by Borregaard, having a molecular weight of 3,500 g / mol and a sulfonation degree of around 0.6 mol / kg,Sulfonated lignin compound L2 is the product Marasperse CBOS-6 (CAS number: 8061-51-6), supplied by Borregaard, having a molecular weight of 5,500 g / mol and a sulfonation degree of around 2.4 mol / kg,Polyoxyalkylene copolymer is the product Pluronic™ PE 10400 (CAS Number: 9003-11-6), supplied by BASF, which is an EO-PO-EO block copolymer,Acrylic graft copolymer is the product Atlox™ 4913-LQ-(MV), supplied by CRODA, which is a solution comprising around 35% by weight of acrylic graft copolymer, andOxygenated hydrocarbon compound is the product Rhodasurf DA / 630-E (CAS Number: 78330-20-8), supplied by SOLVAY-RHODIA, which is a polyethylene glycol alkyl ether.The anti-freeze agent(s), the thickener(s), the biocide(s), and the anti-foam agent(s), used in examples Cl, Il and 12 are components well-known in the art to prepare suspension concentrate, and are the same in each composition.The preparation of the compositions Cl, Il and 12 (detailed in table 1) is described as follows.In a first step (step i), a vessel of suitable size is charged with water, anti-freeze agent(s), biocide(s), anti -foam agent(s), and thickener(s), and all these ingredients are mixed for 30 minutes with a paddle stirrer, at room temperature (25°C), to obtain an homogenized mixture.In a second step (step ii), the sulfonated lignin compound(s) (LI and / or L2) are added portionwise over 45 minutes into the mixture obtained in step i, and the mixture is stirred with a paddle stirrer until the solubilization of the sulfonated lignin compound(s) (when probing a spatula into the mixture, no lumps can be detected).In a third step (step iii), another vessel of suitable size is charged with isocycloseram, emamectin, the polyoxyalkylene copolymer, the acrylic graft copolymer, and the oxygenated hydrocarbon, and all these ingredients are mixed with a high shear mixing (Silverson high-shearmixer, 5000 rpm), at room temperature (25°C). The mixture is sheared continuously until it is able to pass through a 150 pm sieve.The mixture is then milled using a suitable bead mill until the particle size D(v,50) of isocycloseram and emamectin are less than 2 pm, in using a Malvern Mastersizer 3000, laser diffraction particle size analyser.The preparation of the compositions according to the invention, comprising (la) emamectin, (lb) isocycloseram, or (Ic) isocycloseram and emamectin, in the third step, can also be prepared wherein each active ingredient composition is prepared as described above, and thereafter the single active ingredient compositions are mixed together, for example, by mixing for 15-30 mins using a low shear paddle stirrer. Examples of compositions prepared in step iii are gathered in the below table P, and are expressed in percentage by weight over the total weight of the composition (% w / w):Table PIn a fourth step (step iv), the mixture obtained in step iii is added to the mixture obtained in step ii, and the two mixtures are mixed with a paddle stirrer at room temperature (25°C). In step iv, the pH is around 8.0 - 8.5.The same process is followed for the compositions Cl, Il and 12.The concentrations of the ingredients added to form the compositions Cl, Il and 12 are listed in the below table 1, and are expressed in percentage by weight over the total weight of the composition (% w / w).Table 1To evaluate the stability of the compositions Cl, Il and 12, the presence of sludge was determined with the following method: after emptying the composition into a beaker, a glass rod was inserted into the original bottle. If a tacky residue is felt and if the rod is covered in residue, then the presence of sludge is confirmed (“Yes” in Table 2).The results are gathered in table 2 below.Table 2The results in Table 2 show a long-term stability of at least 3 months at 25°C with the compositions II and 12, according to the present invention,2, Compositions comprising emamectinThe components used in table 3 (Experiments 1-9) are detailed below:Emamectin benzoate (CAS number: 155569-91-8),Sulfonated lignin compound LI is the product Vanisperse CB (CAS number: 8061- 51-6), supplied by Borregaard, having a molecular weight of 3,500 g / mol and a sulfonation degree of around 0.6 mol / kg,Polyoxyalkylene copolymer is the product Pluronic™ PE 10400 (CAS Number: 9003-11-6), supplied by BASF, which is an EO-PO-EO block copolymer, Acrylic graft copolymer is the product Atlox™ 4913-LQ-(MV), supplied by CRODA, which is a solution comprising around 35% by weight of acrylic graft copolymer,Oxygenated hydrocarbon compound is the product Rhodasurf DA / 630-E (CAS Number: 78330-20-8), supplied by SOLVAY-RHODIA, which is a polyethylene glycol alkyl ether,- Morwet 425 is naphthalenesulfonic acid, sodium salt condensed with formaldehyde (CAS Number: 68425-94-5),Greensperse S9 is lignosulfonic acid, sodium salt, sulfomethylated,- Borresperse NA is sodium ligninsulfonate powder, and- Ultrazine NA is lignosulfonic acid, sodium salt.The anti-foam agent(s) used in table 3 are components well-known in the art, and are the same in each composition (i.e. Experiments 5-9).Preparation of Emamectin compositionsPluronic PE 10400 was molten in an oven at 50°C before use. A 30ml glass jar was charged with water and the other components accorindg to table 3 (except emamectin benzoate and the anti-foam agent). If the other components did not readily dissolve in water, the mixture was heated in an oven at 40°C and shaken on a Retsch 400 shaker mill for 2x 5 min. The anti-foam agent was added as indicated in the table below. Emamectin benzoate was added to the glass jar on top of the solution. The wetting properties of the solution was visually assessed. 10g of glass beads (1.0-1.2mm) were added and the jar was shaken at 30 s"l for 3x lOmin (or 2x 15min) plus lx 20min using a Retsch 400 shaker mill. Between milling cycles, the mixtures were left to cool for 5min. After completion of the full milling program the viscosity was visually assessed. The particle size was determined using a Malvern Mastersizer 2000 particle size analyzer.Results: Pluronic PE 10400 showed good wetting properties and yielded a composition of low viscosity with an acceptable median particle size d

[0050] <10pm. Also the combination of Pluronic PE 10400 with Atlox 4913-LQ-(MV) showed good wetting properties and yielded a composition with low viscosity and an acceptable median particle size d

[0050] <10pm. But only the addition of Rhodasurf DA / 630-E allowed to reach the target median particle size of d

[0050] <5 pm under otherwise comparable conditions, while maintaining good wetting properties and a low viscosity of the composition.Table 3Typical procedure for producing a large batch of the Emamectin benzoate composition: Pluronic PE 10400 was molten in an oven at 50°C and homogenized. 250g of molten Pluronic PE 10400 was added to 750g of water, to produce a 25% aqueous solution of thepolyoxyalkylene copolymer. The mixture was left on a roller until Pluronic PE 10400 had completely dissolved.To prepare the premix, an 8L double-jacket vessel was charged with 2071g of water. While stirring with a paddle stirrer, 600g of the Pluronic PE 10400 solution (25%), 150g of Atlox 4913-LQ-(MV), 60g of Rhodasurf DA / 630-E and 12g of Dow Corning 1510 anti -foam agent was added. 3109g of Emamectin benzoate (96.5% purity) was slowly added with a scope. Emamectin benzoate was slowly wetted into the liquid by stirring with a paddle stirrer. After the complete amount of Emamectin benzoate had been wetted in, the vessel was connected to a heater / chiller unit and its content was cooled down to 10°C. Afterwards the mixture was homogenized for 2h using a Silverson high-shear mixer equipped with a square-hole screen. A small sample was passed through a 150pm sieve. As only a trace residue was left on the sieve, the premix was decanted into plastic containers.The premix was milled using a Dynomill Multilab bead mill equipped with a 600ml milling chamber, which was charged with 420ml of glass beads (1.0-1.3mm, gap set at 0.3mm). The mantle of the milling chamber was cooled to 2°C. The premix was kept in a double-jacket vessel, which was connected to a chiller unit set to 5°C and equipped with a paddle stirrer. Before starting the bead mill, the milling chamber was filled up with premix using the feed pump at 30 rpm. Then, the mill was started (2389 rpm, tip speed = 8 m / s) and the speed of the feed pump was increased to 55 rpm (approx. 50 L / h). The premix was re-circulated into the jacketed vessel. During milling, the temperature of the composition leaving the mill was found to be around 25-26°C. After 120 min a particle size measurement showed that the particle size d

[0050] in the holding vessel was down to 2.2 pm. The mill was emptied into the holding vessel. The composition in the holding vessel was homogenized for 20 min using the paddle stirrer, before it was decanted plastic containers. The content of Emamectin benzoate was determined by HPLC and was found to be 50.6%w / w. The particle size was found to be d[0.1] = 1.2 pm, d[0.5] = 2.1 pm, and d[0.9] = 3.6 pm.

Claims

CLAIMS1. A composition comprising:(a) isocycloseram,(b) emamectin, preferably emamectin benzoate,(c) from 1 to 12% by weight of a sulfonated lignin compound (LI) having a molecular weight up to 10,000 g / mol, over the total weight of the composition, and(d) from 0 to 12% by weight of a sulfonated lignin compound (L2) having a molecular weight up to 10,000 g / mol, over the total weight of the composition, the compound L2 being different from the compound LI.

2. A composition comprising:(a) isocycloseram,(b) emamectin, preferably emamectin benzoate,(c) a sulfonated lignin compound (LI) having a molecular weight up to 10,000 g / mol, and(d) a sulfonated lignin compound (L2) having a molecular weight up to 10,000 g / mol, the compound L2 being different from the compound LI.

3. A composition according to claim 2, characterized in that it comprises from 1 to 12% by weight of the compound LI, over the total weight of the composition.

4. A composition according to any one of the preceding claims, characterized in that the compound LI has a molecular weight from 1,000 to 8,000 g / mol, preferably from 2,000 to 7,000 g / mol, preferably from 2,500 to 4,500 g / mol, and more preferably from 3,000 to 4,000 g / mol.

5. A composition according to any one of the preceding claims, characterized in that the compound LI has a sulfonation degree from 0.1 to 5.0 mol / kg of the compound LI, preferably from 0.2 to 3.0 mol / kg of the compound LI, preferably from 0.1 to 1.5 mol / kg of the compound LI, and more preferably from 0.2 to 1.0 mol / kg of the compound LI.

6. A composition according to any one of the preceding claims, characterized in that it comprises from 2 to 10% by weight of the compound LI, and preferably from 4 to 9% by weight of the compound LI, over the total weight of the composition.

7. A composition according to any one of the preceding claims, characterized in that the compound L2 has a molecular weight from 1,000 to 8,000 g / mol, preferably from 2,000 to 7,000 g / mol, preferably from 4,500 to 6,500 g / mol, and more preferably from 5,000 to 6,000 g / mol.

8. A composition according to any one of the preceding claims, characterized in that the compound L2 has a sulfonation degree from 0.1 to 5.0 mol / kg of the compound L2, preferably from 0.2 to 3.0 mol / kg of the compound L2, preferably from 1.6 to 3.0 mol / kg of the compound L2, and more preferably from 2.0 to 3.0 mol / kg of the compound L2.

9. A composition according to any one of the preceding claims, characterized in that it comprises from 2 to 10% by weight of the compound L2, and preferably from 4 to 9% by weight of the compound L2, over the total weight of the composition.

10. A composition according to any one of the preceding claims, characterized in that it comprises from 1% to 30% by weight of isocy closeram, and preferably from 10% to 20% by weight of isocy closeram, over the total weight of the composition.

11. A composition according to any one of the preceding claims, characterized in that it comprises from 0.1% to 20% by weight of emamectin, and preferably from 1% to 10% by weight of emamectin, over the total weight of the composition.

12. A composition according to any one of the preceding claims, characterized in that it comprises a weight ratio of isocycloseram to emamectin from 1 : 1 to 10: 1, preferably from 1 : 1 to 8 : 1 , preferably from 1 : 1 to 5 : 1 , and more preferably 2: 1, 3: 1 or 4: 1.

13. A composition according to any one of the preceding claims, characterized in that it further comprises at least one of the components selected among a polyoxyalkylene copolymer, an acrylic graft copolymer, and an oxygenated hydrocarbon.

14. A composition according to claim 13, characterized in that it comprises:- from 0.01% to 10.0% by weight of the polyoxyalkylene copolymer, preferably from 0.1% to 5.0% by weight of the poly oxyalkylene copolymer, and more preferably from 0.5% to 2.0% by weight of the polyoxyalkylene copolymer, over the total weight of the composition,- from 0.01% to 10.0% by weight of the acrylic graft polymer, preferably from 0.01 to 5.0% by weight of the acrylic graft polymer, preferably from 0.1% to 2.0% by weight of the acrylic graft polymer, and more preferably from 0.1% to 1.0% by weight of the acrylic graft polymer, over the total weight of the composition, and- from 0.01% to 5.0% by weight of the oxygenated hydrocarbon compound, preferably from 0.05% to 2.0% by weight of the oxygenated hydrocarbon compound, and more preferably from 0.1% to 1.0% by weight of the oxygenated hydrocarbon compound, over the total weight of the composition.

15. A composition according to any one of the preceding claims, characterized in that it is a suspension concentrate, a flowable suspension, a suspoemulsion, suspension concentratecapsule suspension blends, a ready-to-use bait, wettable powder, water dispersible granules, or water dispersible tablets.

16. A method of combating and / or controlling a pest, which comprises applying to the pest, to a locus of the pest, or to a plant susceptible to attack by the pest, the composition according to any one of the preceding claims.

17. A composition comprising:(b) emamectin, preferably emamectin benzoate, optionally in an amount of from 40 to 60 % by weight over the total weight of the composition;(e) a polyoxyalkylene copolymer in an amount of from 1 to 4% by weight over the total weight of the composition;(f) an acrylic graft copolymer in an amount of from 1 to 4% by weight over the total weight of the composition;(g) an oxygenated hydrocarbon in an amount of from 0.5 to 1.5% by weight over the total weight of the composition; and(h) water.